Data is at the heart of everything we do. “Data” or “big data,” if you will, can be a difficult concept to clearly understand. But data is incredibly powerful. The collection of data in large amounts allows it to be assessed in terms of analytics or applied mathematics. Essentially, it is the study and analysis of data that led to the Tolerance Induction Program and continues to drive our unprecedented outcomes. Data drives the development of each individualized treatment plan for every patient who enters our clinic. Until recently, the data collection and analytics process toward treating patients has involved dozens of individuals, including myself, to ensure the data output is matched toward the patient’s best outcome. Given the sheer volume of new patients seen at TPIRC each month, the design of specific software with the ability to absorb this volume of new patient data and treatment demands is a priority.
As the amount of data we collect and study continues to grow, quite literally to one billion data points, it is imperative that we develop next-generation software that can manage our data and the novel ways we utilize it. This software must be custom developed – there is simply no parallel for what we do in any existing software – and its development will directly impact our ability to scale. Data is woven through our entire process – beginning more than 10 years ago – and will always play a critical role in TPIRC’s success, not only for the diseases we treat today, but those that this model will impact in the future, as well. For each new patient, the data collection process begins from the very onset of treatment with extensive diagnostic testing, and it continues through the study and analysis of that data to identify endotypes, drive treatment models, ensure safety, and open pathways of understanding for patient-directed research and ever-improving treatment models. The key to this process and the ability to replicate the safe and effective growth of our model lies in the development of fully-integrated software.
This is a costly but necessary endeavor. We have already made important strides in 2018, laying the foundation for Phase I of the software’s development, scheduled for a 1st Quarter 2019 preliminary trial. While the full funding for this project is not yet in place, its critical need drives us to move the needle further even as we seek the support necessary to see it through to completion. Our goal is to see Phase I fully implemented, positioning us to open our third and fourth sites in Southern California before the end of the coming year.
- Assembled a dynamic team of software engineers
- Developed a complete machine learning model toward analytics
- Built the framework of the software platform to be used by physicians, scientists, and patients